ArticleAntimicrobial agents and chemotherapy2011
Profiling the Aspergillus fumigatus proteome in response to caspofungin.
Article in Antimicrobial agents and chemotherapy, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 64 citations in OpenAlex.
- Alligamycin A, an antifungal β-lactone spiroketal macrolide from Streptomyces iranensis.Nature communications · 2024Article
- FungiProteomeDB: a database for the molecular weight and isoelectric points of the fungal proteomes.Database : the journal of biological databases and curation · 2023Article
- Heterogeneity in the transcriptional response of the human pathogen Aspergillus fumigatus to the antifungal agent caspofungin.Genetics · 2022Article
- Cytoskeletal Alteration Is an Early Cellular Response in Pulmonary Epithelium Infected with Aspergillus fumigatus Rather than Scedosporium apiospermum.Microbial ecology · 2022Article
- Transcriptional and translational landscape ofComputational and structural biotechnology journal · 2021Article
- An Overview of Genomics, Phylogenomics and Proteomics Approaches in Ascomycota.Life (Basel, Switzerland) · 2020Review
- Biotinylated Surfome Profiling Identifies Potential Biomarkers for Diagnosis and Therapy of Aspergillus fumigatus Infection.mSphere · 2020Article
- Phosphoproteomics of Aspergillus fumigatus Exposed to the Antifungal Drug Caspofungin.mSphere · 2020Article
- Chemical Compositions of Propolis from China and the United States and their Antimicrobial Activities AgainstMolecules (Basel, Switzerland) · 2019Article
- Resistance mechanism and proteins inMycology · 2019Review
- Module-detection approaches for the integration of multilevel omics data highlight the comprehensive response of Aspergillus fumigatus to caspofungin.BMC systems biology · 2018Article
- Scanning Quadrupole Data-Independent Acquisition, Part B: Application to the Analysis of the Calcineurin-Interacting Proteins during Treatment of Aspergillus fumigatus with Azole and Echinocandin Antifungal Drugs.Journal of proteome research · 2018Article
- Molecular Insights Into Development and Virulence Determinants ofFrontiers in cellular and infection microbiology · 2018Review
- Aspergillus fumigatus morphology and dynamic host interactions.Nature reviews. Microbiology · 2017Review
- Genetics, Molecular, and Proteomics Advances in Filamentous Fungi.Current microbiology · 2017Review
- Molecular and cellular responses of the pathogenic fungus Lomentospora prolificans to the antifungal drug voriconazole.PloS one · 2017Article
- Proteomic Insights on the Metabolism ofFrontiers in bioengineering and biotechnology · 2017Article
- Systems Biology Approaches for Host-Fungal Interactions: An Expanding Multi-Omics Frontier.Omics : a journal of integrative biology · 2016Review
- Article
- Methodologies and perspectives of proteomics applied to filamentous fungi: from sample preparation to secretome analysis.International journal of molecular sciences · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution.
Funding
Abstract
The proteomic response of Aspergillus fumigatus to caspofungin was evaluated by gel-free isobaric tagging for relative and absolute quantitation (iTRAQ) as a means to determine potential biomarkers of drug action. A cell fractionation approach yielding 4 subcellular compartment fractions was used to enhance the resolution of proteins for proteomic analysis. Using iTRAQ, a total of 471 unique proteins were identified in soluble and cell wall/plasma membrane fractions at 24 and 48 h of growth in rich media in a wild-type drug-susceptible strain. A total of 122 proteins showed at least a 2-fold change in relative abundance following exposure to caspofungin (CSF) at just below the minimum effective concentration (0.12 μg/ml). The largest changes were seen in the mitochondrial hypoxia response domain protein (AFUA_1G12250), the level of which decreased >16-fold in the secreted fraction, and ChiA1, the level of which decreased 12.1-fold in the cell wall/plasma membrane fraction. The level of the major allergen and cytotoxin AspF1 was also shown to decrease by 12.1-fold upon the addition of drug. A subsequent iTRAQ analysis of an echinocandin-resistant strain (fks1-S678P) was used to validate proteins specific to drug action. A total of 103 proteins in the 2 fractions tested by iTRAQ were differentially expressed in the wild-type susceptible strain but not significantly changed in the resistant strain. Of these potential biomarkers, 11 had levels that changed at least 12-fold. Microarray analysis of the susceptible strain was performed to evaluate the correlation between proteomics and genomics, with a total of 117 genes found to be changing at least 2-fold. Of these, a total of 22 proteins with significant changes identified by iTRAQ also showed significant gene expression level changes by microarray. Overall, these data have the potential to identify biomarkers that assess the relative efficacy of echinocandin drug therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.